BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced the approval of Loramyc in 13 additional European countries through a Mutual Recognition Procedure with France as reference member state.

With this approval to a total of 26 European countries for Loramyc and the recent Setofilm approval in 16 European countries, BioAlliance is building an attractive cancer supportive care portfolio including this two complementary products.

“These remarkable achievements for both Loramyc and Setofilm demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe,” said Dominique Costantini, president and CEO of BioAlliance Pharma. Recent Loramyc approvals: Austria, Bulgaria, Czech Republic, Estonia, Greece, Hungary, Letonia, Lithuania, Poland, Portugal, Romania, Slovak Republic, Slovenia.

Initial Loramyc approvals: Belgium, Germany, Denmark, Finland, France, Italy, Luxemburg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom. Setofilm: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxemburg, Netherlands, Norway, Portugal, Spain, Sweden, UK.

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications.